FIRST REPORT OF THE PHASE-I STUDY OF THE NOVEL ORAL JAK2 INHIBITOR SB1518 IN PATIENTS WITH MYELOFIBROSIS

被引：0
|
作者：
Seymour, F. [1 ]
To, B. [2 ]
Goh, A. [3 ]
Meadows, L. [1 ]
Ethirajulu, A. [3 ]
Wood, A. [3 ]
Zhu, A. [4 ]
Roberts, W. [5 ]
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Australia
[2] Royal Adelaide Hosp, Inst Med & Vet Sci, Adelaide, SA 5000, Australia
[3] S BIO Pty Ltd, Singapore, Singapore
[4] S BIO Pty Ltd, Redwood City, CA USA
[5] Royal Melbourne Hosp, Parkville, Vic 3050, Australia
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1144
引用
收藏
页码：472 / 472
页数：1
相关论文
共 50 条
  • [31] LONG-TERM FOLLOW UP OF A PHASE 1/2 STUDY OF SAR302503, AN ORAL JAK2 SELECTIVE INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF)
    Gotlib, J.
    Pardanani, A.
    Jamieson, C.
    Cortes, J.
    Talpaz, M.
    Stone, R.
    Gao, G.
    Zhang, J.
    Neumann, F.
    Lebedinsky, C.
    Tefferi, A.
    HAEMATOLOGICA, 2012, 97 : 145 - 145
  • [32] A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
    Shah, Neil P.
    Olszynski, Patrycja
    Sokol, Lubomir
    Verstovsek, Srdan
    Hoffman, Ronald
    List, Alan F.
    Cortes, Jorge
    Kantadian, Hagop M.
    Gilliland, D. Gary
    Clary, Douglas O.
    Bui, Lynne A.
    Wadleigh, Martha
    BLOOD, 2008, 112 (11) : 44 - 44
  • [33] Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
    Lancman, Guido
    Mascarenhas, John
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (01) : 23 - 28
  • [34] BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis
    Pardanani, Animesh
    Roberts, Andrew W.
    Seymour, John F.
    Burbury, Kate
    Verstovsek, Srdan
    Kantarjian, Hagop M.
    Begna, Kebede
    Yoshitsugu, Hiroyuki
    Gestone, Toni Ann
    Phillips, Penny
    Xing, Guan
    Peltz, Gerson
    Lorenzi, Matthew V.
    Alland, Leila
    Woolfson, Adrian
    Tefferi, Ayalew
    BLOOD, 2013, 122 (21)
  • [35] Phase I Study Of LY2784544, a JAK2 Selective Inhibitor, In Patients With Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)
    Verstovsek, Srdan
    Mesa, Ruben A.
    Salama, Mohamed E.
    Giles, Jennifer L. K.
    Pitou, Celine
    Zimmermann, Annamaria Hayden
    Price, Gregory L.
    Walgreen, Richard A.
    Prchal, Josef
    BLOOD, 2013, 122 (21)
  • [36] Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
    Verstovsek, Srdan
    Tam, Constantine S.
    Wadleigh, Martha
    Sokol, Lubomir
    Smith, Catherine C.
    Bui, Lynne A.
    Song, Chunyan
    Clary, Douglas O.
    Olszynski, Patrycja
    Cortes, Jorge
    Kantarjian, Hagop
    Shah, Neil P.
    LEUKEMIA RESEARCH, 2014, 38 (03) : 316 - 322
  • [37] A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Polycythemia Vera
    Paquette, Ronald
    Sokol, Lubomir
    Shah, Neil P.
    Silver, Richard T.
    List, Alan F.
    Clary, Douglas O.
    Bui, Lynne A.
    Talpaz, Moshe
    BLOOD, 2008, 112 (11) : 971 - 971
  • [38] A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study
    Zhou, Yile
    Huang, Jian
    Wen, Bingbing
    Zhou, Hu
    Yang, Wei
    Fan, Lianlian
    Gong, Tiejun
    Gao, Sujun
    Jiao, Zongjiu
    Liu, Qingchi
    Zhao, Lidong
    Wu, Guocai
    Wu, Cuicui
    Wang, Jun
    Zhang, Jin
    Fu, Jiaping
    Sheng, Zengmei
    Zhu, Zunmin
    Lu, Jian
    Zhang, Yi
    Jin, Jie
    BLOOD, 2024, 144 : 1808 - 1809
  • [39] A CASE STUDY OF RESENSITIZATION TO RUXOLITINIB, A JAK1/JAK2 INHIBITOR, IN A PATIENT WITH MYELOFIBROSIS (MF)
    Gisslinger, H.
    Skrabs, C.
    Gisslinger, B.
    Schoder, R.
    Muellauer, L.
    Kralovics, R.
    HAEMATOLOGICA, 2013, 98 : 346 - 347
  • [40] Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib
    Saha, Chandan
    Harrison, Claire
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (07) : 583 - 595
12345